Physician profile
Andrea Johnson
NPI 1740486455
$1,824.02
in general payments reported to CMS, 2019-2025
22 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $148 · 2021: $250 · 2022: $118 · 2023: $100 · 2024: $424 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $344.78 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $181.63 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.41 | 2019-2025 | Jardiance |
| Csl Behring | $131.00 | 2019-2024 | Kcentra |
| Astrazeneca Pharmaceuticals LP | $129.06 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Procept Biorobotics Corporation | $121.42 | 2024 | Aquabeam System |
| Lilly USA, LLC | $112.62 | 2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $91.48 | 2019 | |
| Glaxosmithkline, LLC. | $81.54 | 2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $76.58 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $70.42 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $66.36 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $48.72 | 2019-2023 | Verquvo |
| Ucb, INC. | $41.77 | 2019 | |
| Exact Sciences Corporation | $32.53 | 2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31.05 | 2019 | |
| Philips North America LLC | $21.55 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.76 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $18.31 | 2025 | Nexletol |
| Vapotherm INC | $18.01 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $17.44 | 2024 | |
| Lundbeck LLC | $14.58 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.